213 related articles for article (PubMed ID: 26379078)
1. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.
Punnoose EA; Ferraldeschi R; Szafer-Glusman E; Tucker EK; Mohan S; Flohr P; Riisnaes R; Miranda S; Figueiredo I; Rodrigues DN; Omlin A; Pezaro C; Zhu J; Amler L; Patel P; Yan Y; Bales N; Werner SL; Louw J; Pandita A; Marrinucci D; Attard G; de Bono J
Br J Cancer; 2015 Oct; 113(8):1225-33. PubMed ID: 26379078
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
[TBL] [Abstract][Full Text] [Related]
3. Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.
Kwan EM; Dai C; Fettke H; Hauser C; Docanto MM; Bukczynska P; Ng N; Foroughi S; Graham LK; Mahon K; Tan W; Wang X; Zhao Z; Zheng T; Zhou K; Yu J; Du P; Horvath LG; Jia S; Kohli M; Azad AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250422
[TBL] [Abstract][Full Text] [Related]
4. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
6. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B
BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Lozano JJ; Jiménez N; García-Recio S; Erill N; Gaba L; Tagliapietra A; Ortega V; Carrera G; Colomer A; Gascón P; Mellado B
Oncotarget; 2015 Apr; 6(12):10604-16. PubMed ID: 25871394
[TBL] [Abstract][Full Text] [Related]
8. Identification of
Pearson HB; Li J; Meniel VS; Fennell CM; Waring P; Montgomery KG; Rebello RJ; Macpherson AA; Koushyar S; Furic L; Cullinane C; Clarkson RW; Smalley MJ; Simpson KJ; Phesse TJ; Shepherd PR; Humbert PO; Sansom OJ; Phillips WA
Cancer Discov; 2018 Jun; 8(6):764-779. PubMed ID: 29581176
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.
Hotte SJ; Chi KN; Joshua AM; Tu D; Macfarlane RJ; Gregg RW; Ruether JD; Basappa NS; Finch D; Salim M; Winquist EW; Torri V; North S; Kollmannsberger C; Ellard SL; Eigl BJ; Tinker A; Allan AL; Beja K; Annala M; Powers J; Wyatt AW; Seymour L;
Clin Genitourin Cancer; 2019 Jun; 17(3):201-208.e1. PubMed ID: 31056399
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.
Greene SB; Dago AE; Leitz LJ; Wang Y; Lee J; Werner SL; Gendreau S; Patel P; Jia S; Zhang L; Tucker EK; Malchiodi M; Graf RP; Dittamore R; Marrinucci D; Landers M
PLoS One; 2016; 11(11):e0165089. PubMed ID: 27851748
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
[TBL] [Abstract][Full Text] [Related]
13. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
14. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer.
Magbanua MJ; Sosa EV; Scott JH; Simko J; Collins C; Pinkel D; Ryan CJ; Park JW
BMC Cancer; 2012 Feb; 12():78. PubMed ID: 22373240
[TBL] [Abstract][Full Text] [Related]
15. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.
Cho WJ; Oliveira DS; Najy AJ; Mainetti LE; Aoun HD; Cher ML; Heath E; Kim HR; Bonfil RD
J Transl Med; 2016 Mar; 14():72. PubMed ID: 26975354
[TBL] [Abstract][Full Text] [Related]
16. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
[TBL] [Abstract][Full Text] [Related]
17. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
18. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
20. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A
Clin Cancer Res; 2023 May; 29(10):1952-1968. PubMed ID: 36862086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
